Generation Bio(US:GBIO)2025-03-13 20:10Financial Performance - Generation Bio reported a cash balance of $185.2 million as of December 31, 2024, down from $264.4 million as of December 31, 2023, expected to fund operations into the second half of 2027[5][11]. - The net loss for Q4 2024 was $21.4 million, or $0.32 per share, compared to a net loss of $35.2 million, or $0.53 per share, in Q4 2023[6][12]. - The total operating expenses for the year ended December 31, 2024, were $162.3 million, an increase from $144.5 million in 2023[6][12]. - A non-cash charge of $3.6 million was recognized in Q4 2024 related to the termination of the lease for the manufacturing facility, totaling $63.2 million for the year[6][12]. - Total assets decreased to $231.2 million as of December 31, 2024, from $374.8 million as of December 31, 2023[11]. Research and Development - Research and development (R&D) expenses for Q4 2024 were $15.5 million, a decrease from $27.9 million in Q4 2023, while total R&D expenses for the year were $61.3 million compared to $93.6 million in 2023[6][12]. - Generation Bio achieved approximately 98% knockdown of the B2M protein in human T cells using its T cell-selective lipid nanoparticle (LNP) in both in vitro and mouse studies[4]. - The company plans to announce the target and indication for its lead ctLNP-siRNA program in mid-2025 and submit an investigational new drug (IND) application in the second half of 2026[4][5]. General and Administrative Expenses - General and administrative (G&A) expenses for Q4 2024 were $8.7 million, down from $13.4 million in Q4 2023, with total G&A expenses for the year at $37.8 million compared to $50.9 million in 2023[6][12]. Collaboration Revenue - Collaboration revenue for Q4 2024 was $4.2 million, compared to $2.9 million in Q4 2023, with total collaboration revenue for the year at $19.9 million versus $5.9 million in 2023[6][12].